Glycosmedia Weekly Diabetes News - 09/11/2020

Potential Unrealized Mortality Benefit of GLP‐1 Receptor Agonists and SGLT2 Inhibitors

This analysis indicates unrealized opportunities to reduce mortality in selected Veterans with T2D and CAD via increased use of GLP‐1RA and SGLT2i (Diabetes, Obesity and Metabolism)

Lower Cardiorenal Risk with Sodium‐Glucose Cotransporter‐2 Inhibitors versus Dipeptidyl Peptidase‐4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases

In this multinational observational study, SGLT2i was associated with lower risk of heart failure and chronic kidney disease versus DPP4i in T2D patients otherwise free from both cardiovascular and renal disease (Diabetes, Obesity and Metabolism)

Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes

Overall, the improved postprandial blood glucose levels and increase in incretins observed in the absence of changes in insulin sensitivity and gluconeogenesis, support an enteroinsular mechanistic pathway in youth with type 2 diabetes treated with short-term metformin (Diabetologia)